Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, now holds B shares in Novozymes A/S to a total of 24,556,257 shares of a nominal value of DKK 49,112,514, equivalent to 7.56% of Novozymes A/S’ share capital and 3.04% of the voting rights. The announcement is a result of Baillie Gifford Overseas Limited, a wholly owned subsidiary of Baillie Gifford & Co, increasing its holding of B shares in Novozymes A/S to a total of 16,349,463 B shares of a nominal value of DKK 32,698,926, equivalent to 5.03% of Novozymes share capital.
Major Shareholder Announcement
In accordance with section 29 of the Danish Securities Trading Act, Novozymes hereby announces that it has been informed that Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has decreased its holding of B shares in Novozymes to 7.56%, previously reported at 7.64% (a decrease of 0.08%).
| Source: Novonesis (Novozymes A/S)
Attachments
Recommended Reading
-
Novonesis expands global footprint with acquisition of production facility in Southeast Asia Investment of around USD 50 million strengthens fermentation capabilities and supports the company’s...
Read More -
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016,...
Read More